Connect with us

BUSINESS

Cara Therapeutics Inc (NASDAQ:CARA) Will Report Topline Data Of Pivotal KALM-2 Phase 3 Trial Of KORSUVA Injection In Q2 2020: Will Submit NDA For KORSUVA Injection To FDA

Published

on

Cara Therapeutics Inc (NASDAQ:CARA) is on track to provide topline data for the pivotal KALM-2 Phase 3 clinical trial of KORSUVA injection in Q2 2020. The company is conducting phase 3 clinical trial of KORSUVA injection in hemodialysis patients suffering from CKD-ap. It will also submit NDA (New Drug Application) for KORSUVA injection to the US FDA in Q2.

CEO and President of Cara, Derek Chalmers said under the updated guidance of the FDA the company is on track to report topline data from KALM-2 in Q2 despite the ongoing coronavirus crisis. He further said the company is making significant progress in phase 3 clinical trial of KORSUVA injection that comprises supportive safety data.

Evaluates Oral KORSUVA for atopic dermatitis

Cara is conducting phase 2 clinical trials on oral KORSUVA for the treatment of atopic dermatitis in patients suffering from moderate to severe pruritus, and patients suffering from hepatic impairment due to PBC (primary biliary cholangitis), and patients with pruritus. The company will conclude an interim statistical analysis in Q2 for the ongoing phase 2 trial in patients with atopic dermatitis. It will present the data from the previous positive phase 2 dose clinical trial of Oral KORSUVA to cure pruritus in patients suffering from moderate to severe CKD at the National Kidney Foundation Spring Clinical Meeting.

KALM-2 phase 3 clinical trial

The placebo-controlled, randomized, multicenter 12-week phase 2 trial evaluates the efficacy and safety of 0.5 mcg/kg KORSUVA injection in four hundred thirty patients suffering from moderate to severe pruritus. In the primary efficacy end-point, a proportion of the patients should at least achieve a three-point improvement in the weekly mean data of the 24‑hour Worst Itching Intensity Numeric Rating Scale daily at the end of week 12.

Cara has reported the topline data from phase 3 KALM-1 US trials in May 2019. It has achieved the primary end-point along with a significant improvement. The trial also accomplished the secondary end-point and the patients have well tolerated the KORSUA injection during a 12-week treatment.

Cara is pleased to announce that Derek will take part in the 19th Annual Needham Healthcare Conference on April 15, 2020. The investors can access web recording from its website.

Continue Reading
Advertisement

BUSINESS

NewLeaf Brands Inc (OTCMKTS:NLBIF) Will Take Over Mydecine Group; Add 37.5% Stake In Trellis Holdings Oregon

Published

on

NewLeaf Brands Inc (OTCMKTS:NLBIF) informed the shareholders about its recent developments. We Are Kured, which belongs to NewLeaf, introduced innovative CBD flower pre-rolled joints on April 9. The company received an overwhelming response from the customers. To meet the growing demand from customers, the company expects to improve the distribution network in the US.­­

Inks share swap deal with Levee Street Holdings, LLC

NewLeaf entered a share swap pact on April 23, 2020, with Levee Street Holdings, LLC, to acquire a stake of 50% for CAD 450,000. Levee Street is established to venture into an alternative beverage like CBD products. Greg Kassanoff founded companies such as Levee Street, and Pioneer Wine and Spirits. He is also working as CEO at MPWS (Mexcor Pioneer Wine and Spirits), which maintains several restaurants and retail relationships across Texas.

The network developed by Greg is playing a vital role in introducing a product line of NewLeaf across the state of Texas. CEO of NewLeaf, Joshua Bartch, said its team is working hard to become a leading player in product categories like hemp, mushroom, and cannabis.

Signs definitive accord to takeover Mydecine Group

NewLeaf entered pact on April 29, 2020, to take over a vertically integrated firm – Mydecine Group, which uses wellness, health, and medicinal properties of compounds available in mushrooms.

Takes over 37.5% stake in Trellis Holdings Oregon, LLC

NewLeaf signed an accord on May 5, 2020, to clinch a 37.5% stake in Trellis Holdings Oregon, LLC. As per the terms of share exchange the deal, NewLeaf will acquire all of the issued and outstanding capital of Trellis from Benjamin Martch and David Joshua Bartch.

Trellis, which owns several licenses with OLCC in the Oregon state, conducts business operations in recreational and medical cannabis. The company also maintains recreational cannabis cultivation on eleven-acre land in Southern Oregon. In Portland, Oregon, Trellis operates recreational and medical cannabis dispensaries. The company seeks additional licenses to improve canopy cultivation outdoor on 40,000 Sq. Ft.

Appoints chief operating officer and chief scientific officer

NewLeaf inducted Robert Roscow as CSO and Damon Michaels as COO on May 12, and 11 2020.  The company entered a share exchange deal on May 21, 2020, to acquire MindLeap Health Inc., an advanced telemedicine platform.

Continue Reading

BUSINESS

SinglePoint, Inc. (OTCMKTS:SING) Posts Solid Growth Of 300% In Q1 2020 Revenues

Published

on

SinglePoint, Inc. (OTCMKTS:SING) has reported revenues of $1.075 million (up 300%) in Q1 2020. The projects developed in Q4 2019 and the acquisition of Direct Solar helped the company report stellar growth in Q1.

Record solar bookings in Q4 2019

Direct Solar holds stellar solar bookings in the previous quarter; it expanded its business to 30 states from the prevailing seven markets. It clocked residential sales of more than 40 in February 2020. However, the company’s sales declined in March on account of the coronavirus crisis.

Contactless sales

Direct Solar adopted a digital sales platform to facilitate contactless sales, which helped to venture into the new markets quickly. The company also achieved cost savings by switching over to the digital sales platform.

Healthy growth in the solar business

Direct Solar maintains excellent solar bookings that comprise accretive and incremental commercial sales and residential bookings. The company began experiencing the impact of coronavirus in late Q1 and more prominent in Q2.

Chairman and CEO of SinglePoint, Greg Lambrecht, said 1606 Original Hemp Product and Direct Solar America contribute to its revenue growth. The company will realign its business opportunities and take action to boost growth.

The company has outperformed in Q1 by surpassing the revenue of $1 million. However, it expects to face the coronavirus impact on Q2 revenues because of business disruptions. SinglePoint expects to post solid growth in Q3 and Q4 by unveiling innovative products and changing the sales strategies.

Initiatives to double sales in Q2

The hemp vertical of SinglePoint expects to double the sales in Q2. SinglePoint is also unveiling Hemp 1606 6-pack counter display. The company realized sales growth of 133% in Q1 from 1606 Hemp compared to the previous quarter.

SinglePoint hired talented sales professionals to promote in-store products. They will also play a vital role in acquiring new stores to sell its products soon. The aim of 1606 Hemp is to record over 250 retail accounts across several states.

SinglePoint expects to generate revenues of up to $5.5 million by offering its products to 1,000 stores. On the successful rollout of Hemp 1606, the company has added 250 accounts in four weeks.

Continue Reading

BUSINESS

Golden Leaf Holdings Ltd (OTCMKTS:GLDFF) Posts Record Revenues Of $4.7 Million In Q1 2020

Published

on

Golden Leaf Holdings Ltd (OTCMKTS:GLDFF) reported an increase of 21% in revenues to $4.7 million in Q1 2020. Chalice farms contributed revenues of $3.1 million. The company adopted measures like reducing operational spending, improving warehouse efficiencies, and extending terms with the suppliers to realize better growth in Q1.

Achievements in Q1

Golden Leaf unveiled the RXO product line on January 8, 2020, leveraging its patented technology – Essential Innovations. The product is offered in Tanker, Shatter, and Vaporizer varieties. It will sell these innovative products in Washington, Nevada, and California using the partnerships for manufacturing established in Q1. Golden Leaf is experiencing growing demand for its Fruit Chews in both retail and wholesale channels.

Inks an accord to takeover Tozmoz

Golden Leaf inked an accord to take over one of the leading cannabis extractors in Oregon – Tozmoz on February 3, 2020. Established in 2015, Tozmoz provides extraction processes like ethanol, hydrocarbon, and Co2 for wiped film and short path distribution. Its additional services include packaging services, product formulation, and manufacturing.

Commenting on this deal, Jeff said the company is working with Tozmoz for several years now, and this takeover squarely fits into its business strategy. The acquisition allows the company to build and expand its product line. Golden Leaf acquired all the assets like a facility based in Clackamas of Tozmoz for $2.8 million.

Post takeover, Tozmoz co-founders – Jerry Wallis and Joel Klobas, will continue to offer their services to Golden Leaf. Also, Golden Leaf will employ Klobas as its Vice President (manufacturing). Jerry will provide consultancy services to Senior Vice President (operations) and Vice President (production).

To tackle the upcoming coronavirus crisis, Golden Leaf expedited the unveiling of home delivery service on March 20, 2020. Golden Leaf signed a product distribution and manufacturing accord on March 13, 2020, with Sugar Pine for the manufacture of marijuana-infused products.

CEO of Golden Leaf, Jeff Yapp, said the company appointed John Ford to ensure distributional and operation growth by implementing best standards and practices. Golden Leaf has given the charge of Interim Chief Finance Officer to its president ‘Stanley Grissinger.’

Continue Reading



Trending Stories